Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).
Pastina P, Nardone V, Botta C, Croci S, Tini P, Battaglia G, Ricci V, Cusi MG, Gandolfo C, Misso G, Zappavigna S, Caraglia M, Giordano A, Aldinucci D, Tassone P, Tagliaferri P, Pirtoli L, Correale P. Pastina P, et al. Among authors: misso g. Oncotarget. 2017 Aug 24;8(44):75904-75913. doi: 10.18632/oncotarget.20411. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100279 Free PMC article.
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).
Correale P, Marra M, Remondo C, Migali C, Misso G, Arcuri FP, Del Vecchio MT, Carducci A, Loiacono L, Tassone P, Abbruzzese A, Tagliaferri P, Caraglia M. Correale P, et al. Among authors: misso g. Eur J Cancer. 2010 Jun;46(9):1703-11. doi: 10.1016/j.ejca.2010.03.005. Eur J Cancer. 2010. PMID: 20399639
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients.
Correale P, Botta C, Basile A, Pagliuchi M, Licchetta A, Martellucci I, Bestoso E, Apollinari S, Addeo R, Misso G, Romano O, Abbruzzese A, Lamberti M, Luzzi L, Gotti G, Rotundo MS, Caraglia M, Tagliaferri P. Correale P, et al. Among authors: misso g. Cancer Biol Ther. 2011 Jul 15;12(2):112-8. doi: 10.4161/cbt.12.2.15722. Epub 2011 Jul 15. Cancer Biol Ther. 2011. PMID: 21525780 Clinical Trial.
Tumour-specific uptake of anti-cancer drugs: the future is here.
Caraglia M, Marra M, Misso G, Lamberti M, Salzano G, De Rosa G, Abbruzzese A. Caraglia M, et al. Among authors: misso g. Curr Drug Metab. 2012 Jan;13(1):4-21. doi: 10.2174/138920012798356871. Curr Drug Metab. 2012. PMID: 22292808 Review.
Molecular targets for the treatment of multiple myeloma.
Rossi M, Di Martino MT, Morelli E, Leotta M, Rizzo A, Grimaldi A, Misso G, Tassone P, Caraglia M. Rossi M, et al. Among authors: misso g. Curr Cancer Drug Targets. 2012 Sep;12(7):757-67. doi: 10.2174/156800912802429300. Curr Cancer Drug Targets. 2012. PMID: 22671925 Review.
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.
Amodio N, Di Martino MT, Foresta U, Leone E, Lionetti M, Leotta M, Gullà AM, Pitari MR, Conforti F, Rossi M, Agosti V, Fulciniti M, Misso G, Morabito F, Ferrarini M, Neri A, Caraglia M, Munshi NC, Anderson KC, Tagliaferri P, Tassone P. Amodio N, et al. Among authors: misso g. Cell Death Dis. 2012 Nov 29;3(11):e436. doi: 10.1038/cddis.2012.175. Cell Death Dis. 2012. PMID: 23190608 Free PMC article.
76 results